The COVID-19 pandemic could wipe out most of Edwards Lifesciences Corp. projected revenue growth in 2020, but the company's leadership remains hopeful that procedure volumes can return to normal by the end of the year.
As hospitals and clinics around the world focus their limited resources on COVID-19 patients, they are cancelling or postponing many other procedures. These deferrals include not only "elective" procedures, but...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?